SAN DIEGO—Cytiva has launched its Sefia next-generation manufacturing platform, with the goal of helping drug developers and larger healthcare providers accelerate their production of chimeric antigen ...
The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...
Non-CHO cell expression systems gain traction as faster, more flexible alternatives for biologics manufacturing.
Automated cell therapy manufacturing pioneer Cellares has hit a key milestone, gaining a current Good Manufacturing Practice (cGMP) stamp of approval for its Cell Shuttle factory-in-a-box, which is ...
Cell Therapy Manufacturers · GlobeNewswire Inc. Dublin, March 02, 2026 (GLOBE NEWSWIRE) -- The "Cell Therapy Manufacturing Market (7th Edition): Trends and Forecast Till 2035 - Distribution by Type of ...
Analysts expect the market for manufacturing cell and gene therapies, worth less than $20 billion in 2024, to expand rapidly as approvals drive higher volumes of production.
The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results